Business

Bruker Corporation to Present at the 41st Annual J.P. Morgan Healthcare Conference

BILLERICA, Mass.--(BUSINESS WIRE)-- Bruker Corporation (Nasdaq: BRKR) announced today it will participate in the 41st annual J.P. Morgan Healthcare

articleBruker CorporationDecember 21, 20224/company/bruker-corporation/news/bruker-corporation-to-present-at-the-41st-annual-jp-morgan-healthcare-conference
Bruker Corporation to Present at the 41st Annual J.P. Morgan Healthcare Conference

About this update from Bruker Corporation

[{"type":"text","content":" BILLERICA, Mass.--(BUSINESS WIRE)--\nBruker Corporation (Nasdaq: BRKR) announced today it will participate in the 41st annual J.P. Morgan Healthcare Conference in San Francisco. Frank Laukien, Chairman, President & CEO, Mark Munch, Executive Vice President & President of Bruker Nano Group, and Gerald Herman, Executive Vice President & CFO will present on behalf of the Company on Monday, January 9th, 2023 at 10:30 AM Eastern Standard Time.\n\nA live audio webcast of the presentation will be available on the Investor Relations section of the Company's website at https://ir.bruker.com. A replay of the presentation will be posted in the “Events & Presentations” section of the Bruker Corporation Investor Relations website after the event and will be available for 30 days following the presentation.\n\nAbout Bruker Corporation (Nasdaq: BRKR)\n\nBruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in life science molecular research, in applied and pharma applications, in microscopy and nanoanalysis, and in industrial applications, as well as in cell biology, preclinical imaging, clinical phenomics and proteomics research and clinical microbiology. For more information, please visit: www.bruker.com.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20221221005583/en/\n\nInvestors:\nJustin Ward\nSenior Director, Investor Relations & Corporate Development\n+1 (978) 663-3660 x1479\[email protected]\n\nSource: Bruker Corporation","length":3725,"tagName":"div"}]

More updates from Bruker Corporation